Current approaches in nanostructured biomaterials in treatment of leiomyosarcoma

Abstract

One form of uncommon cancer that develops in the smooth muscles is called leiomyosarcoma, or LMS. The body’s hollow organs, such as the stomach, bladder, intestines, and blood vessels, contain smooth muscles. The three main components of conventional therapy are surgery, chemotherapy, and radiotherapy. These treatments have numerous drawbacks, including insufficient surgical resection, drug resistance to chemotherapy, radiotherapy insensitivity, and postoperative bone defects. Because of their easy modification, targeting, and other characteristics, along with their unique physicochemical properties, nanoparticles have been used extensively in research on anti-leiomyosarcoma treatment. Inhibiting the onset and progression of leiomyosarcoma, nanoparticles can have a variety of effects on the growth of leiomyosarcoma cells. We provide a brief overview of the development of nanoparticle research closely associated with leiomyosarcoma treatment in this review.

Keywords

Leiomyosarcoma (LMS) / Nanoparticles / Nano-based biomaterials / Anti-leiomyosarcoma treatment

References

[1] Kerrison WGJ, Thway K, Jones RL, Huang PH. The biology and treatment of leiomyosarcomas. Crit Rev Oncol Hematol. 2023;184(March):103955.

[2] Mankin HJ, Casas-Ganem J, Kim J Il, Gebhardt MC, Hornicek FJ, Zeegen EN. Leiomyosarcoma of somatic soft tissues. Clin Orthop Relat Res. 2004;421(421):225–231.

[3] Gammon JM, Dold NM, Jewell CM. Improving the clinical impact of biomaterials in cancer immunotherapy. Oncotarget. 2016;7(13):15421–15443.

[4] Zhang Q, Kuang G, Zhang L, Zhu Y. Nanocarriers for platinum drug delivery. Biomed Tech. 2023;2(November 2022):77–89.

[5] Feng C, Jiang Y, Wang T, et al. Recent advances on nanostructured biomaterials in osteosarcoma treatment. Coord Chem Rev. 2023;493(March):215315.

[6] Alsawaftah NM, Awad NS, Pitt WG, Husseini GA. pH-responsive nanocarriers in cancer therapy. Polymers (Basel). 2022;14(5).

[7] Fernandes C, Suares D, Yergeri MC. Tumor microenvironment targeted nanotherapy. Front Pharmacol. 2018;9(October):1–25.

[8] Phua SZF, Xue C, Lim WQ, et al. Light-responsive prodrug-based supramolecular nanosystems for site-specific combination therapy of cancer. Chem Mater. 2019;31(9):3349–3358.

[9] Zhu J, Wang J, Li Y. Recent advances in magnetic nanocarriers for tumor treatment. Biomed Pharmacother. 2023;159(November 2022):114227.

[10] Chen H, Yao Y. Progress of biomaterials for bone tumor therapy. J Biomater Appl. 2022;36(6):945–955.

[11] Wang X, Meng F, Lei Z, Fan D, Lou B. Editorial: bone targeting nanoparticle drug delivery system in bone metabolism and bone-related tumor diseases. Front Pharmacol. 2022;13(September):1–2.

[12] Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov. 2022;21(11):799–820.

[13] Hu G, Guo M, Xu J, et al. Nanoparticles targeting macrophages as potential clinical therapeutic agents against cancer and inflammation. Front Immunol. 2019;10(AUG):1–14.

[14] Shen H, Huang H, Jiang Z. Nanoparticle-based radiosensitization strategies for improving radiation therapy. Front Pharmacol. 2023;14(February):1–7.

[15] Gong L, Zhang Y, Liu C, Zhang M, Han S. Application of radiosensitizers in cancer radiotherapy. Int J Nanomed. 2021;16:1083–1102.

[16] Igaz N, Szőke K, Kovács D, et al. Synergistic radiosensitization by gold nanoparticles and the histone deacetylase inhibitor SAHA in 2D and 3D cancer cell cultures. Nanomaterials. 2020;10(1).

[17] Damasco JA, Ravi S, Perez JD, Hagaman DE, Melancon MP. Understanding nanoparticle toxicity to direct a safe-by-design approach in cancer nanomedicine. Nanomaterials. 2020;10(11):1–41.

[18] Goel A, Kulshrestha S. Biomaterials as therapeutic agents for treatment of cancer: a review. IOP Conf Ser Mater Sci Eng. 2021;1116(1):012037.

[19] Yang F, Shi K, Jia Y peng, Hao Y, Peng J rong, Qian Z yong. Advanced biomaterials for cancer immunotherapy. Acta Pharmacol Sin. 2020;41(7):911–927.

[20] Alavi M, Hamidi M. Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles. Drug Metab Pers Ther. 2019;34(1):1–8.

[21] Wang S, Chen Y, Guo J, Huang Q. Liposomes for tumor targeted therapy: a review. Int J Mol Sci. 2023;24(3):1–25.

[22] Xiao M, Tang Q, Zeng S, et al. Emerging biomaterials for tumor immunotherapy. Biomater Res. 2023;27(1):1–52.

[23] Nsairat H, Khater D, Sayed U, Odeh F, Al Bawab A, Alshaer W. Liposomes: structure, composition, types, and clinical applications. Heliyon. 2022;8(5):e09394.

[24] Navya PN, Kaphle A, Srinivas SP, Bhargava SK, Rotello VM, Daima HK. Current trends and challenges in cancer management and therapy using designer nanomaterials. Nano Converg. 2019;6(1).

[25] Yu L, Sun M, Zhang Q, Zhou Q, Wang Y. Harnessing the immune system by targeting immune checkpoints: providing new hope for Oncotherapy. Front Immunol. 2022;13(September):1–20.

[26] Pelaz B, Alexiou C, Alvarez-Puebla RA, et al. Diverse applications of nanomedicine. ACS Nano. 2017;11(3):2313–2381.

[27] Din FU, Aman W, Ullah I, et al. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int J Nanomed. 2017;12:7291–7309.

RIGHTS & PERMISSIONS

2024 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.